ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO

  • Post author:
  • Post category:Newsroom

ERYTECH reported complete Phase III results of its pivotal program with GRASPA® in Acute Lymphoblastic Leukemia (ALL) and presented the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). During an investigator meeting ERYTECH also presented the progress and plans on other development programs.